ArticleCancer immunology, immunotherapy : CII2025

Cadonilimab, a PD-1/CTLA-4 bispecific antibody in unresectable hepatocellular carcinoma: a real-world study.

Yilin Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.